drugset / Trial / NCT03818815

A Study to Assess the Safety, Tolerability and Efficacy of OP0201 as an Adjunct Treatment for Acute Otitis Media in Infants and Children Aged 6 to 24 Months

NCT03818815

Phase 2 Completed 103 enrolled Novus Therapeutics, Inc
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to develop a better understanding of the safety, tolerability and efficacy of intranasal OP0201 as an adjunct treatment to oral antibiotics for the treatment of Acute Otitis Media (AOM) in infants and children.

Timeline

Start
2019-02-21
Primary completion
2020-03-09
Completion
2020-03-26

Drugs

EvaluationDrugModalityDoseRoute
Subject OP0201 Unknown 10 mg Intranasal
Comparator Amoxicillin Other / unclassified 90 mg/kg Oral

Indications